OrganiGram Holdings Inc., through its subsidiaries, produces and sells dried cannabis and cannabis oil in Canada. It also offers wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis oils to retailers and wholesalers. The company also exports its products. It sells its products online, as well as through phone orders. OrganiGram Holdings Inc. was founded in 2013 and is headquartered in Moncton, Canada.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone844-644-4726
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$9.73 million
Profitability
Miscellaneous
Employees615
Next Earnings Date11/25/2019 (Confirmed)
OptionableNot Optionable
OrganiGram (NASDAQ:OGI) Frequently Asked Questions
What is OrganiGram's stock symbol?
OrganiGram trades on the NASDAQ under the ticker symbol "OGI."
How were OrganiGram's earnings last quarter?
OrganiGram Holdings Inc (NASDAQ:OGI) released its quarterly earnings data on Monday, July, 15th. The company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of $0.02 by $0.09. The company earned $30.36 million during the quarter, compared to analyst estimates of $30.81 million. The company's revenue for the quarter was up 782.6% compared to the same quarter last year. View OrganiGram's Earnings History.
When is OrganiGram's next earnings date?
What price target have analysts set for OGI?
7 equities research analysts have issued 12 month price objectives for OrganiGram's shares. Their forecasts range from $8.20 to $17.10. On average, they anticipate OrganiGram's share price to reach $10.96 in the next twelve months. This suggests a possible upside of 372.4% from the stock's current price. View Analyst Price Targets for OrganiGram.
What is the consensus analysts' recommendation for OrganiGram?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OrganiGram in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for OrganiGram.
Has OrganiGram been receiving favorable news coverage?
News headlines about OGI stock have been trending very negative on Wednesday, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. OrganiGram earned a media sentiment score of -3.9 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for OrganiGram.
Are investors shorting OrganiGram?
OrganiGram saw a increase in short interest during the month of October. As of October 15th, there was short interest totalling 4,280,000 shares, an increase of 46.1% from the September 15th total of 2,930,000 shares. Based on an average daily volume of 1,300,000 shares, the days-to-cover ratio is currently 3.3 days. Currently, 2.9% of the shares of the stock are sold short. View OrganiGram's Current Options Chain.
Who are some of OrganiGram's key competitors?
Some companies that are related to OrganiGram include Epizyme (EPZM), Nabriva Therapeutics (NBRV), Dicerna Pharmaceuticals (DRNA), Constellation Pharmaceuticals (CNST), Innoviva (INVA), Enanta Pharmaceuticals (ENTA), BELLUS Health (BLUSF), Supernus Pharmaceuticals (SUPN), Y-mAbs Therapeutics (YMAB), Radius Health (RDUS), Esperion Therapeutics (ESPR), Odonate Therapeutics (ODT), Arvinas (ARVN), Endo International (ENDP) and Theravance Biopharma (TBPH).
What other stocks do shareholders of OrganiGram own?
Who are OrganiGram's key executives?
OrganiGram's management team includes the folowing people:
- Mr. Greg Engel, CEO & Director (Age 54)
- Mr. Paolo De Luca C.A., C.F.A, Chief Financial Officer (Age 46)
- Mr. Jeff Purcell, VP - Operations
- Mr. Timothy Emberg, Sr. VP of Sales & Commercial Operations
- Mr. Peter R. Hanson, Director of Fin.
Who are OrganiGram's major shareholders?
OrganiGram's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Commonwealth Equity Services LLC (0.06%), Sigma Planning Corp (0.04%), Cambridge Investment Research Advisors Inc. (0.02%), Traynor Capital Management Inc. (0.02%), Signition LP (0.02%) and Sfmg LLC (0.02%).
Which institutional investors are buying OrganiGram stock?
OGI stock was bought by a variety of institutional investors in the last quarter, including Sigma Planning Corp, Cambridge Investment Research Advisors Inc., Signition LP, Archford Capital Strategies LLC, Wedbush Securities Inc., Commonwealth Equity Services LLC, Traynor Capital Management Inc. and Sfmg LLC.
How do I buy shares of OrganiGram?
Shares of OGI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is OrganiGram's stock price today?
One share of OGI stock can currently be purchased for approximately $2.32.
How big of a company is OrganiGram?
What is OrganiGram's official website?
How can I contact OrganiGram?
OrganiGram's mailing address is 35A ENGLISH DR., MONCTON A3, E1E 3X3. The company can be reached via phone at 844-644-4726.
MarketBeat Community Rating for OrganiGram (NASDAQ OGI)
MarketBeat's community ratings are surveys of what our community members think about OrganiGram and other stocks. Vote "Outperform" if you believe OGI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OGI will underperform the S&P 500 over the long term. You may vote once every thirty days.
